Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 9,877 shares at $65.99 ($641K) on 2021-02-11, disclosed to the SEC on 2021-02-16.
Open-market sale of $641k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.85 | 447 | $28K | 4.4% |
| 2 | $63.74 | 1,460 | $93K | 14.5% |
| 3 | $63.74 | 1,460 | $93K | 14.5% |
| 4 | $64.93 | 1,272 | $83K | 12.9% |
| 5 | $64.93 | 1,272 | $83K | 12.9% |
| 6 | $65.99 | 1,845 |
| $122K |
| 19.0% |
| 7 | $65.99 | 1,845 | $122K | 19.0% |
| 8 | $67.05 | 262 | $18K | 2.7% |
| 9 | $68.05 | 14 | $953 | 0.1% |
| Total | $64.94 avg | 9,877 | $641K | 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |